会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • USE
    • 使用
    • WO2007085970A2
    • 2007-08-02
    • PCT/IB2007/001186
    • 2007-01-26
    • DANISCO A/SRAUTONEN, NinaPUTAALA, HeliOUWEHAND, ArthurTIIHONEN, Kirsti
    • RAUTONEN, NinaPUTAALA, HeliOUWEHAND, ArthurTIIHONEN, Kirsti
    • A61K35/745A61K35/747
    • A61K35/747A23K10/18A23K50/40A23K50/75A23L33/135A23L33/30A61K35/745
    • Use of at least one strain of a microorganism and/or a metabolite thereof in the manufacture of a support for administration to a subject for modulating satiety signalling, wherein the support is a pharmaceutically acceptable support or a food product. Suitably, the at least one strain of a microorganism and/or a metabolite thereof may be administered to the subject for the treatment and/or prevention of excess weight and/or a disease caused by excess weight. Likewise, the at least one strain of a microorganism and/or a metabolite thereof is administered to the subject for the treatment and/or prevention of obesity and/or a disease caused by obesity. Preferably, the microorganism is a probiotic microorganism. Suitably the microorganism may be a lactic acid bacterium. Li one embodiment the microorganism is a strain of Lactobacillus spp. and/or Bifidobacterium spp., for example a strain of Lactobacillus acidophilus, L. curvatus, L. salivarius and/or B. lactis.
    • 至少一种微生物菌株和/或其代谢物在制备用于施用受试者以调节饱腹感信号的载体中的用途,其中所述载体是药学上可接受的载体或食品。 适当地,将微生物和/或其代谢物的至少一种菌株施用于受试者以治疗和/或预防超重和/或由超重引起的疾病。 同样地,向受试者施用至少一种微生物和/或其代谢物,用于治疗和/或预防肥胖症和/或由肥胖引起的疾病。 优选地,微生物是益生菌微生物。 适当地,微生物可以是乳酸菌。 李一个实例是微生物是一种乳杆菌属菌株。 和/或双歧杆菌属,例如嗜酸乳杆菌,弯曲曲霉,唾液乳杆菌和/或乳酸乳杆菌的菌株。
    • 7. 发明申请
    • METHOD
    • 方法
    • WO2005032567A2
    • 2005-04-14
    • PCT/IB2004/003273
    • 2004-09-24
    • DANISCO A/SRAUTONEN, NinaNURMI, JussiNURMINEN, PäiviPUOLAKKAINEN, Pauli
    • RAUTONEN, NinaNURMI, JussiNURMINEN, PäiviPUOLAKKAINEN, Pauli
    • A61K35/74
    • A61K35/745A23K10/16A23K10/18A23K50/75A61K31/19A61K31/205A61K45/06A61K2300/00
    • The present invention relates to the use of a microorganism and/or a metabolite thereof to at least increase the amount of a COX-1 mRNA in a cell. The present invention further relates to the use of a microorganism and/or a metabolite thereof in the manufacture of a medicament to treat the side effects associated with nonsteroidal anti­inflammatory drugs (NSAIDs). The present invention further relates to a pharmaceutical preparation comprising in combination a nonsteroidal anti­inflammatory drug (NSAIDs) and a microorganism and/or a metabolite thereof which is capable of at least increasing the amount of a COX-1 mRNA in a cell. The present invention yet further relates to a pharmaceutical preparation comprising in combination betaine or a pharmaceutically acceptable salt thereof and a microorganism and/or a metabolite thereof which is capable of at least increasing the amount of a COX-1 mRNA in a cell. The microorganism may suitably be a bacterium, preferably from the genus Bifidobacterium.
    • 本发明涉及使微生物和/或其代谢物至少增加细胞中COX-1mRNA的量的用途。 本发明还涉及微生物和/或其代谢物在制备用于治疗与非甾体抗炎药(NSAID)相关的副作用的药物中的用途。 本发明还涉及一种药物制剂,其包含非甾体抗炎药(NSAID)和能够至少增加细胞中COX-1mRNA量的微生物和/或其代谢物的组合。 本发明还涉及包含组合甜菜碱或其药学上可接受的盐和能够至少增加细胞中COX-1 mRNA的量的微生物和/或其代谢物的药物制剂。 微生物可以适当地是细菌,优选来自双歧杆菌属。